A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
| Status: | Completed |
|---|---|
| Conditions: | Ovarian Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/27/2013 |
| Start Date: | October 2011 |
| End Date: | April 2015 |
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
To determine whether the combination of MM-121 plus paclitaxel is more effective than
paclitaxel alone
This is a multicenter, open-label, randomized, Phase II study of MM-121 in patients with
platinum resistant or refractory recurrent/advanced ovarian cancers. Up to 210 patients
will be randomized (2:1) to receive MM-121 plus paclitaxel or paclitaxel alone.
Inclusion Criteria:
- Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube
cancer or primary peritoneal cancer
- Received at least one prior platinum based chemotherapy regimen
- Platinum-resistant or refractory
- Eligible for weekly paclitaxel
- Adequate liver and kidney function
- 18 years of age or above
Exclusion Criteria:
- Evidence of any other active malignancy
- History of severe allergic reactions to paclitaxel or other drugs formulated in
Cremophor®EL
We found this trial at
10
sites
535 Barnhill Dr
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
(888) 600-4822
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials